December 12, 2024

Melanoma Recurrence Signs with ATLAS Guide

Conexiant

December 12, 2024

54 Novel Drugs Await FDA Review

An analysis published in the American Journal of Health-System Pharmacy provides an overview of the potential next wave of pharmaceuticals.

Conexiant

December 12, 2024

Key Genetic Variants in Palmoplantar Keratoderma

In a Danish cohort of 142 patients with palmoplantar keratoderma, researchers identified DSP variants linked to cardiomyopathy risk in seemingly typical cases, highlighting why genetic testing matters beyond just diagnosis.

Conexiant

December 12, 2024

Phase 3 Data: Nemolizumab for Prurigo Nodularis Relief

Conexiant

December 10, 2024

ASCVD Risk Elevated in Cutaneous Lupus

Conexiant

November 26, 2024

Do Cancer Drugs Trigger Skin Issues?

Conexiant

November 22, 2024

FDA Approves Bimzelx for Hidradenitis Suppurativa

Bimzelx is the first hidradenitis suppurativa treatment selectively targeting both interleukin-17A and interleukin-17F.

Conexiant

November 21, 2024

Deuruxolitinib Shows Promise for Alopecia

Deuruxolitinib achieved significant hair regrowth in a Phase 3 clinical trial. 

Conexiant

November 21, 2024

Dr. Martin Makary Next FDA Leader?

Dr. Makary has served as an adviser to Washington conservative health care think tank Paragon Health Institute.

Reuters